» Articles » PMID: 38075199

MiR-765 As a Promising Biomarker for Low-dose Radiation-induced Pulmonary Fibrosis

Overview
Date 2023 Dec 11
PMID 38075199
Authors
Affiliations
Soon will be listed here.
Abstract

High-dose radiation (HDR) is widely used for cancer treatment, but the effectiveness of low-dose radiation (LDR) in the treatment of various diseases is controversial. Therefore, to safely utilize LDR for therapeutic purposes, further research on its numerous biological effects of LDR is required. Interest in the increased use of medical imaging devices or the effects of surrounding living environmental radiation on the human body, particularly on fibrosis, is rapidly increasing. Therefore, this study aimed to verify the relationship between LDR and pulmonary fibrosis by evaluating the changes in fibroblasts after LDR treatment and their associated signaling mechanisms. LDR increased the expression of fibrosis markers COL1A1 and α-SMA, cell proliferation, and migration by activating YAP1 and Twist in fibroblasts. Meanwhile, miRNA was employed as a tool to inhibit LDR-induced fibrosis and it was found that miR-765 simultaneously targeted COL1A1, α-SMA, and YAP1. At the cellular level, miR-765 reduced the proliferation and migration of fibroblasts by suppressing the expression of LDR-induced fibrosis factors COL1A1, α-SMA, and YAP1. The efficacy of miR-765 was confirmed using bleomycin (BLM)-induced fibrotic mouse model. The characteristics of pulmonary fibrosis were reduced after injection of miR-765-overexpressing cells into BLM-induced fibrotic mice. In addition, the suppression of miR-765 expression in the plasma of patients with pulmonary fibrosis confirmed the negative relationship between pulmonary fibrosis and miR-765 expression. Therefore, this study demonstrates that miR-765 is a potential novel diagnostic biomarker and major target for the development of therapeutic agents to inhibit pulmonary fibrosis.

Citing Articles

Atomoxetine suppresses radioresistance in glioblastoma via circATIC/miR-520d-5p/Notch2-Hey1 axis.

Seok H, Choi J, Lee D, Shin I, Bae I Cell Commun Signal. 2024; 22(1):532.

PMID: 39501373 PMC: 11536942. DOI: 10.1186/s12964-024-01915-0.

References
1.
Straub J, New J, Hamilton C, Lominska C, Shnayder Y, Thomas S . Radiation-induced fibrosis: mechanisms and implications for therapy. J Cancer Res Clin Oncol. 2015; 141(11):1985-94. PMC: 4573901. DOI: 10.1007/s00432-015-1974-6. View

2.
Seegenschmiedt M, Katalinic A, Makoski H, Haase W, Gademann G, Hassenstein E . Radiation therapy for benign diseases: patterns of care study in Germany. Int J Radiat Oncol Biol Phys. 2000; 47(1):195-202. DOI: 10.1016/s0360-3016(99)00537-4. View

3.
Sieland J, Niederer D, Engeroff T, Vogt L, Troidl C, Schmitz-Rixen T . Changes in miRNA expression in patients with peripheral arterial vascular disease during moderate- and vigorous-intensity physical activity. Eur J Appl Physiol. 2022; 123(3):645-654. PMC: 9684818. DOI: 10.1007/s00421-022-05091-2. View

4.
Lo T . Radiation therapy for heterotopic ossification. Semin Radiat Oncol. 1999; 9(2):163-70. DOI: 10.1016/s1053-4296(99)80006-x. View

5.
Chen Y, Zhao X, Sun J, Su W, Zhang L, Li Y . YAP1/Twist promotes fibroblast activation and lung fibrosis that conferred by miR-15a loss in IPF. Cell Death Differ. 2019; 26(9):1832-1844. PMC: 6748107. DOI: 10.1038/s41418-018-0250-0. View